Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
MarketWatch8h
Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
Dr Reddys Stocks: Dr. Reddy's Laboratories ended the previous trading day at Rs 1272.20.
Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Business Insider1d
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong ...
ndtvprofit14h
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
cnbctv1815h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
ndtvprofit11h
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Reduce Dr. Reddy's Laboratories; target of Rs 1335 Prabhudas Lilladher
Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...